Limits...
Multidrug-resistant tuberculosis around the world: what progress has been made?

Falzon D, Mirzayev F, Wares F, Baena IG, Zignol M, Linh N, Weyer K, Jaramillo E, Floyd K, Raviglione M - Eur. Respir. J. (2014)

Bottom Line: Multidrug-resistant tuberculosis (MDR-TB) (resistance to at least isoniazid and rifampicin) will influence the future of global TB control. 88% of estimated MDR-TB cases occur in middle- or high-income countries, and 60% occur in Brazil, China, India, the Russian Federation and South Africa.Notification, treatment enrolment and outcome data were summarised for 30 countries, accounting for >90% of the estimated MDR-TB cases among notified TB cases worldwide.Median treatment success was 53% (interquartile range 40-70%) in the 25 countries reporting data for 30 021 MDR-TB cases who started treatment in 2010.

View Article: PubMed Central - PubMed

Affiliation: Global TB Programme, World Health Organization, Geneva, Switzerland falzond@who.int.

No MeSH data available.


Related in: MedlinePlus

a) New and b) retreatment tuberculosis cases with drug-susceptibility test results for isoniazid and rifampicin, 2012, by country. Inadequate linkage between clinical and laboratory registers may result in an overestimation of drug-susceptibility testing coverage (e.g. >100% in Kazakhstan).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4318660&req=5

Figure 1: a) New and b) retreatment tuberculosis cases with drug-susceptibility test results for isoniazid and rifampicin, 2012, by country. Inadequate linkage between clinical and laboratory registers may result in an overestimation of drug-susceptibility testing coverage (e.g. >100% in Kazakhstan).

Mentions: 19 countries provided data for 2012 on the coverage of DST for isoniazid and rifampicin among new patients (median 1.6% (IQR 0.1–78.1%)) (fig. 1a). In previously treated TB patients, DST coverage also ranged widely among the 22 countries providing data (10.6% (2.1–46.3%)). Seven eastern European countries and Peru reported DST results for >20% of new patients, and Belarus and Kazakhstan reported >80% of previously treated cases with DST results. The targets of the “The Global Plan to Stop TB 2011–2015” are 20% in new and 100% in previously treated TB cases (table 1 [13]. In the 15 countries with data for 2012, the coverage of DST for both fluoroquinolones and second-line injectable drugs among MDR-TB patients was 43.0 (15.5–69.5) (data by country not shown).


Multidrug-resistant tuberculosis around the world: what progress has been made?

Falzon D, Mirzayev F, Wares F, Baena IG, Zignol M, Linh N, Weyer K, Jaramillo E, Floyd K, Raviglione M - Eur. Respir. J. (2014)

a) New and b) retreatment tuberculosis cases with drug-susceptibility test results for isoniazid and rifampicin, 2012, by country. Inadequate linkage between clinical and laboratory registers may result in an overestimation of drug-susceptibility testing coverage (e.g. >100% in Kazakhstan).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4318660&req=5

Figure 1: a) New and b) retreatment tuberculosis cases with drug-susceptibility test results for isoniazid and rifampicin, 2012, by country. Inadequate linkage between clinical and laboratory registers may result in an overestimation of drug-susceptibility testing coverage (e.g. >100% in Kazakhstan).
Mentions: 19 countries provided data for 2012 on the coverage of DST for isoniazid and rifampicin among new patients (median 1.6% (IQR 0.1–78.1%)) (fig. 1a). In previously treated TB patients, DST coverage also ranged widely among the 22 countries providing data (10.6% (2.1–46.3%)). Seven eastern European countries and Peru reported DST results for >20% of new patients, and Belarus and Kazakhstan reported >80% of previously treated cases with DST results. The targets of the “The Global Plan to Stop TB 2011–2015” are 20% in new and 100% in previously treated TB cases (table 1 [13]. In the 15 countries with data for 2012, the coverage of DST for both fluoroquinolones and second-line injectable drugs among MDR-TB patients was 43.0 (15.5–69.5) (data by country not shown).

Bottom Line: Multidrug-resistant tuberculosis (MDR-TB) (resistance to at least isoniazid and rifampicin) will influence the future of global TB control. 88% of estimated MDR-TB cases occur in middle- or high-income countries, and 60% occur in Brazil, China, India, the Russian Federation and South Africa.Notification, treatment enrolment and outcome data were summarised for 30 countries, accounting for >90% of the estimated MDR-TB cases among notified TB cases worldwide.Median treatment success was 53% (interquartile range 40-70%) in the 25 countries reporting data for 30 021 MDR-TB cases who started treatment in 2010.

View Article: PubMed Central - PubMed

Affiliation: Global TB Programme, World Health Organization, Geneva, Switzerland falzond@who.int.

No MeSH data available.


Related in: MedlinePlus